The academic institutions involved are the Memorial Sloan Kettering Cancer Center, the University of Pennsylvania, the University of Texas M.D. Anderson Cancer Center, Stanford, and the University of California campuses in San Francisco and Los Angeles.
After decades of frustration, researchers have finally figured out how to direct the body’s immune system to recognize and attack tumors, resulting in some striking recoveries for patients on the brink of death. But this approach has worked for only a minority of patients, so there is still much room for improvement.
Dozens of companies are pursuing the field, and philanthropists are supporting research. Johns Hopkins University recently announced it would open a center for immunotherapy research using $50 million gifts from Michael R. Bloomberg, the former mayor of New York, and Sidney Kimmel, founder of the Jones Apparel Group. Immunotherapy is also a major thrust of Vice President Joseph R. Biden Jr.’s “cancer moonshot” initiative.
Mr. Parker said that his institute, which will involve about 300 researchers in 40 laboratories on the six campuses, will try to improve on existing approaches in ways not being pursued by companies.
The institute will have a somewhat unusual arrangement with the research centers. While each academic center will own the intellectual property from its work, the Parker Institute will manage the patents and their licensing to companies. Some of the proceeds will go toward future research by the Parker Institute and be shared by all the academic centers, giving them an incentive to cooperate rather than compete.
The Parker Institute will also work with companies, including a study with Merck on why some cancers resist treatment by the company’s drug Keytruda. Jeffrey Bluestone, a professor and immune system expert at the University of California, San Francisco, will also serve as chief executive of the Parker Institute, which will be…